Anti-Inflammatory Treatment of Schizophrenia
Summary
Despite current antipsychotic treatment, the majority of people with schizophrenia continue to exhibit persistent positive and negative symptoms and cognitive impairments. An alternative approach to the use of psychotropic agents for the treatment of persistent symptoms is the use of anti-inflammatory agents to reverse the pro-inflammatory state hypothesized to underlie the symptom and sign manifestations of the illness. The investigators primary hypothesis is that add-on anti-inflammatory combination therapy will have significant beneficial effects on persistent positive symptoms and cognitive impairments. The investigators secondary hypotheses are: 1. add-on anti-inflammatory combination therapy will be associated with improvements in depressive and negative symptoms and a reduction in pro-inflammatory cytokines 2. add-on anti-inflammatory combination therapy compared to placebo will not be associated with elevated adverse risk.
Timeline
- Start
- 2012-06
- Primary completion
- 2017-04-17
- Completion
- 2017-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluvastatin | Other / unclassified | 40 mg | — |
| Subject | Salsalate | Small molecule | 4 g | — |
| Subject | docosahexaenoic | Other / unclassified | 2 g | — |
| Subject | eicosapentaenoic | Other / unclassified | 2 g | — |